[ Price : $8.95]
FDA approves Bristol-Myers Squibbs Cobenfy (xanomeline and trospium chloride) capsules for treating schizophrenia in adults.[ Price : $8.95]
Federal Register notice: FDA seeks consumer organizations interested in participating in the selection process for voting or nonvo...[ Price : $8.95]
Federal Register notice: FDA announces that four information collections have been approved by OMB.[ Price : $8.95]
The U.S. 9th Circuit Court of Appeals reverses an earlier California lower court decision that ruled a stem cell treatment firm is...[ Price : $8.95]
An investigation by the journal Science questions the data behind a Parkinsons drug under development by Prothena and based on fal...[ Price : $8.95]
FDA grants Eli Lilly full approval for Retevmo (selpercatinib) for certain adult and pediatric patients two years of age and older...[ Price : $8.95]
AbbVie files a BLA seeking accelerated approval for Teliso-V (telisotuzumab vedotin) and its use in certain adult patients with pr...[ Price : $8.95]
AbbVie says a pivotal Phase 3 (TEMPO-1) trial for tavapadon in early Parkinsons disease met its primary and secondary endpoints.